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2Introduction
Since 1993, ephedra has been the source of tremendous controversy.1 The FDA has received more complaints
on ephedra and products containing the synthetic form of ephedra (ephedrine) than any other dietary sup-
plement available to consumers.2 According to the Journal of Toxicology, ephedra-based supplements have
resulted in cardiac eects, HTN, intracerebral hemorrhage, nephrolithiasis, mania, and death.3 More mild
reactions include dizziness, headache, gastrointestinal stress, irregular heartbeat, and heart palpitations.4
The FDA has documented more than 40 deaths and more than hundreds of serious injuries, but the ac-
curacy of these numbers have come under suspicion due to the reporting procedures used to collect the
data.5
In January of 1999, the FDA listed ephedra at the top of its priority list for dietary supplements.6 This
announcement falls on the heals of some dramatic deaths and strokes that have received extensive press
coverage such as the death of Anne Marie Capati.7 She died after a physical trainer-nutritionist gave her a
list of herbal supplements to take despite her eorts to inform him of her high blood pressure condition that
required her to take medication.8
In February of 2001, a strong message was sent to the makers of ephedra products to the tune of $13.3
million dollars intended to compensate Rosalie and Daniel Talbert for Rosalie's ensuing stroke after use of
1Catherine Monahan, Herbal Wonder or Worry? Delicious Living! (January, 2001)
2Jennifer Sardina, Misconceptions and Misleading Information Prevail|Less Regulation Does Not Mean Less Danger to
Consumers: Dangerous Herbal Products, Journal of Law & Health (1999-2000) (14 JLHEALTH 107).
3M. Wahl, C. Grant, & R. Jesperson, Acute Psychosis from a Dietary Weight Control Supplement, Journal of Toxicology:
Clinical Toxicology, no. 5, vol. 38, pg. 522 (August 1, 2000).
4FDA Statement of Street Drugs Containing Botanical Ephedrine, April 10, 1996.
5Tara Parker-Pope, Ephedra Use Grows, but is it Safe for Dieters?, Asian Wall Street Journal, (4/9/01).
6House Report 106-1053. Activities of the House Committee on Government Reform, One Hundred Sixth Congress First
and Second Sessions (1999-2000).
7Raul D. Reingold, Herbal Supplements May Be Dangerous, Trial, vol. 35, issue 12 (November 1, 1999).
8Capati v. Crunch Fitness Int'l, No. 113218 (N.Y. Sup. Ct. led June 28, 1999). One product recommended and taken,
Thermadrene, contained \20 mg of active ephedra, 150 mg guarana seed, 80 mg caeine, 75 mg purple willow bark, 60 mg
cayenne pepper, and 40 mg ginger root."
3the E'Ola product that was determined to contain ephedrine without indication of the ingredient on the
packaging.9 This case does not apply directly to ephedra cases because the problem with this product was
its synthetic ephedrine content, although, it signies one of the diculties with ephedra. Precisely because
the product ingredient label stated ephedra and not ephedrine, it qualies as a dietary supplement, which
does not fall under the realm of the FDA's supervisory safety obligations.10 The FDA will be holding a
public forum soon to further discuss the future of ephedra.11
What is Ephedra?
Ephedra, also known as ma huang, contains the ephedrine alkaloid that stimulates the central nervous
system.12 Ephedrine alkaloids have an adrenaline like eect on the body|it \excites the nervous system,
opens blood vessels, and stimulates the heart."13 The ephedra sinica plant contains ephedrine alkaloids that
are used in the herbal supplements once they have been cultivated from the dried stems of the plant.14 Some
of the main alkaloids in ephedra are ephedrine and pseudoephedrine, which can be found in OTC drugs, but
an important distinction is that the alkaloids in OTC drugs are produced synthetically.15 Synthetic ephedrine
is more potent than the ephedrine alkaloids found in ephedra.16 Used mainly as a bronchial decongestant,
9E'ola Appealing $13.3 Mil. Ephedrine Supplement Verdict, The Tan Sheet, vol. 9, issue 7 (February 12, 2001) (2001 WL
7868266).
10Dietary Supplement Health and Education Act of 1994, Pub.L. No. 103-417
1165 FR 17510 (April 3, 2001).
12Tod L. Stewart, Getting High with a Little Help from the FEDS: Federal Regulation of Herbal Stimulants, Journal of
Pharmacy & Law, (1997) (6 JPHARML 101).
13Hearings Before the House Government Reform Committee on Ma-Huang: Ancient and Modern Historical Perspectives.
Daniel B. Mowrey, PH.D., 106th Congress (1999).
14What is Ephedra? The Ephedrine Education Council www.ephedrafacts.com
15Paul D. Rheingold, The Prospects for PPA and Ephedra Litigation|and How it Diers From Prescription Drug Cases,
Mealey's Emerging Drugs & Devices, vol. 28 (January 18, 2001)
16See supra www.ephedrafacts.com
4ephedrine is found in bronchodialators such as Primatene, while pseudoephedrine is commonly utilized in
decongestants such as Sudafed.17 Physiologically, it acts to \expand breathing passages, constrict blood
vessels, and increase arterial blood pressure."18 It is the increase in arterial blood pressure that causes
severe hypertension, stroke, or heart attack.19
It has gained notoriety for its use as an herbal supplement that is commonly found in weight loss products
today.20 Athletic individuals have also been using the product to reduce their fat to muscle weight ratio.21
High school and college students have taken advantage of it to study for long periods of time or late into
the night.22Many truck drivers purchase it at truck stops to help them stay awake on the road, and some
people have even used ephedrine-based products for their diuretic eect.23 A more dangerous application
of ephedrine is its use to produce amphetamine/hallucinogenic drugs such as ecstacy.24 Knock of street
drugs such as herbal ecstacy promising \euphoric stimulation" have added to the confusion over the safety
of ephedra.25
17Jerey A. Crossman, Mark McGwire Does It, So Why Can't I? High School Student Use of Dietary Supplements and the
Failure of DSHEA, 28 Capital University L.Rev. 617-657.
18See supra Note 2.
19Jody Aaron, Death Over the Counter: Dangers of Ephedrine, Trial, (December 1, 1997) (1997 WL 9957878).
20Ephedra on the Ropes, Vitamin Research Products, Inc. Nutritional News (October, 1996) http://www.vrp.com
21See supra Note 17.
22See supra Note 19.
23See supra Note 2 and see id.
24See supra Note 17.
25See id.
5The History of Ephedra
Ephedra has been used in a several dierent ways (e.g., respiratory infections, asthma, hay fever, chills,
lack of perspiration, headache, and arthritis) in Traditional Chinese Medicine for more than 5000 years.26
Ephedra plants were not used only in China, in fact, references to the plant date back to 1500B.C. in India.27
It is documented that the Romans used ephedra as well.28 Usage of ephedra in the United States is not new
either (early American settlers used it for tea{known as Mormon tea).29 Once an extensive study on the
safety of ephedra was completed by Chen and Schmidt in 1930, doctors in the U.S. began to prescribe the
synthetic form as a treatment for arthritis.30 In the 1940s, doctors began to prescribe it more aggressively
for asthma|asthma dosages of 150 mg per day were not uncommon.31 Like many other drugs used in
Western medicine, the synthetic form was derived in a laboratory, which eliminates the dependency on a
broker of the herbs.32 Even aspirin, now synthetically formulated, was derived from the bark of willow and
poplar trees.33 A laboratory setting makes it possible for companies to have ultimate control and benet
from nancial savings.
26Mark Blumenthal and Penny King, Ma Huang: Ancient Herb, Modern Medicine, Regulatory Dilemma, 34 Herbal Gram
22, 25 (Summer 1995).
27See supra Note 13.
28See id.
29See id.
30See supra Note 19 and see id.
31See supra Note 13.
32See id.
33Heart Eects of Herbal Medicine, Harvard Heart Letter, vol. 10, (March 1, 2000).
6New Uses of Ephedra
While ephedrine has been widely used since the 1930's in the U.S., it has only recently been discovered to
enhance thermogenesis, which is the process by which calories are burnt in order to generate heat.34 This
information led to the use of ephedrine in diet pills such as Phen-fen and ephedra in the herbal alternatives.
Besides being marketed as a fat burner, ephedra is also marketed for its energy enhancing capabilities.35
With increasing demands on our time, these supplements could seem like a \healthy" alternative to caeine,
despite the fact that caeine is often found in the product as well. It has also become a popular and less
expensive alternative for kids to get a legal \natural" high, but due to the deaths this product caused, many
states have since banned products like herbal ecstacy or made any ephedrine-based products available only
with a prescription.36
A single product that claims to curb your appetite, increase your energy level, and cause your metabolism
to speed up sounds like a wonder pill if there ever was one. These companies can capitalize on the fact that
obesity is a growing problem in America. The sales volume reached $278.9 million for diet pills, showing an
increase of 89.6 percent over the sales volume for 1999.37 More than 97 million adults qualify as obese or
overweight in the United States.38 The Centers for Disease Control has documented that the rate of obesity
among people ages two to twenty has about doubled from what it was ten years ago.39 This younger portion
of the population has been increasingly using products with ephedrine to address this problem. The fact
that most people equate natural with safe has proven to be fatal for some young teens that have overdosed
on supplements with ephedrine alkaloids.
34See supra Note 13.
35Tod Stewart, Getting High with a Little Help From the Feds: Federal Regulation of Herbal Stimulants, Journal of Pharmacy
and Law (1997).
36See supra Note 17.
37Diet Pills, Chain Drug Review, vol. 23, pg. 56, (January 1, 2001).
38Elena Portyansky Beyzarov, Battling the Bulge, Drug Topics, vol. 144, pg. 51, (August 21, 2000).
39Marketing to Teens a Complex Issue, Chain Drug Review, vol. 23, pg. 29 (April 9, 2001).
7Generally, Americans are obsessed with losing weight and are inclined to take the quick-x route whenever
possible. This mentality coupled with a more is better attitude is responsible for the abuse of ephedra based
products and subsequent deaths. Because natural products are equated with safety, many people believe
there are no toxic repercussions for exceeding the recommended dose of a natural dietary supplement.40 This
misperception leads to the occurrence of overdoses.41 A lack of consumer awareness regarding the dangerous
eects of this herb is at the root of this problem.
The dietary supplement industry needs to take responsibility for their role in this lack of knowledge trans-
ference. The Internet poses the largest hurdle to overcome in terms of false claims. Many products are even
described as 100% FDA approved with no side eects.42 Given the circumstances in the case of Capati, it is
reasonable to assume that she would not have knowingly risked her life by talking the supplements had she
known of the dangers and problems associated with combination of prescription drugs and supplements she
ingested.
Manufacturing Situations of Concern
Beyond the isolated question of the safety of ephedra, there are other considerations regarding safety, although
these are not specic to the ephedra herb. Manufacturers stand to make enormous prots from fraudulent
ingredients or claims.43 There are additional issues not listed below, but I have chosen the ones that
most apply to ephedra. Based on historical occurrences of these situations with herbs, these concerns
40See supra Note 3.
41Joshua H. Beisler, Dietary Supplements and Their Discontents: FDA Regulation and the Dietary Supplement Health and
Education Act of 1994, Rutgers L.J. 511-551 (Winter 2000).
42142 C.R. 5582 (comments by Sen. Alfonse D'Amato).
43John S. Williamson, and Christy M. Wyandt, The Herbal Generation: Legal and Regulatory Considerations, Drug Topics,
pg. 101, (April 19, 1999).
8are legitimate, and given the serious nature of the physical eects ephedra can have, these factors merit
discussion.44
1.
Dangerous Drug-herbal Interactions45
2. Unreliability of Labels (amounts of herbs)46
3. Fraudulent substitution|as in \chuifong tokuwan", pills contained modern drugs in addition to lead
and cadmium along with the herbs without indication on the label.47 As mentioned earlier, a more recent
and relevant instance of this concern occurred in the E'Ola and Talbert case in which ephedra was replaced
with ephedrine.
Combining Ephedra with Stimulants
Another recent issue surrounding ephedra concerns combinations of ephedra with other stimulants like caf-
feine or kola nut and the irregularity of dosages of ephedra in products, that is in part a result of the dierent
methods and environments used by suppliers.48 According to the hearing testimony before the House Gov-
ernment Reform Committee on Ma Huang, Dr. Mowrey stated that adding stimulants to ephedra products
is not done to increase the stimulant eect, but rather to \disinhibit brown adipose tissue thermogenesis
thereby assuring a relatively small dose of ephedrine will be eective."49
This concept runs counter to the popular rationales given for the use of stimulants in addition to ephedra.
Some combinations occur unknowingly, such as in the case of Capati and her prescription medicine. In other
44W. Marvin Davis, Dietary Supplements: Are they Safe and Reliable?, Drug Topics, (4/16/01) (2001 WL 8119145).
46See id.
47See id.
48See supra Note 41.
49See supra Note 13.
9instances, those who consume caeine in foods or drinks should also be on alert of the eects additional
stimulants can have. A study performed at the University of California at San Francisco commented on the
addition of stimulants to ephedra products and warned that there is a dangerous potentiation eect.50
Alternatively, according to Dr. Mowrey's testimony before the House Government Reform Committee,
caeine additions to ephedra within products is not dangerous and is in fact necessary to produce the
desired eect when used to address obesity.51 Research demonstrates that a minimum of 20 mg of ephedrine
alkaloids and 200 mg of caeine three times per day is required in order to be eective{a level that far exceeds
the recently proposed FDA regulation on the standardization of ephedrine alkaloid quantities.52 Although,
even Dr. Mowrey acknowledges that many less scrupulous companies add other substances to the ephedra
based products, and it is those substances that are often the culprits of the adverse eects.53 He recommends
some form of standardization within reason that is derived from scientic research.54 A more aware and
informed public is necessary in preventing tragic misuses of ephedra, but part of the current problem is the
mixed information that exists. It is dicult to get a clear understanding of the safety of ephedra because
news articles, the FDA, and trade associations barrage the American public with conicting messages.
The need for more research on dietary supplements was recognized in 1992 when the United States Pub-
lic Health Service established the Oce of Alternative Medicine within the National Institutes of Health
(NIH).55 In 1995, the Oce of Dietary Supplements (ODS) was created by NIH.56 In 1998, the National
Center for Complementary & Alternative Medicine (NCCAM) replaced the Oce of Alternative Medicine.57
50See supra Note 15.
51See supra Note 13.
52See supra Note 13.
53See id.
54See id.
55See supra Note 43.
56H.R. Rep. 106-645, see also www.dietary-supplements.info.nih.gov
57See supra Note 43.
10It was established, among other purposes, to evaluate herbal medicine.58 The United States Pharmacopoeia
(USP) has also stated that it is working on creating a monograph for ephedra.59 These are steps in the right
direction in the quest to ascertain the safety of dietary supplements such as ephedra and to demystify them.
Dosage Standards
The lack of standard dosage amounts of ephedrine alkaloids is a troubling issue to tackle because of the
lack of the FDA authority to regulate the industry, but a recent proposed regulation in 1997 attempted
to do just that|more than 8 mg per serving would qualify the supplement as adulterated or labeling that
suggested more than a daily intake of 24 mg or more than 8 mg within 6 hours would fall under regulation
according to the Federal Food, Drug, and Cosmetic Act (FDCA) section 402(a)(1) and (f)(1).60 It also
limited consumption to one week on the label of a product.61 This proposal would have returned broad
authority to the FDA to regulate this herb because the rule did not attempt to dene serious or adverse.62
This proposal was not well received by the public. Restricting the dosage of the product alarms people and
the industry because the action is perceived as a potentially slippery slope and because there is an enormous
discrepancy regarding the necessity and eectiveness of such a drastic reduction.63 About 60 percent of
Americans take dietary supplements and they demand unfettered access to these products.64 Part of the
58See id.
59See supra Note 43.
60Stephen H. NcNamara, A. Wes Siegner, Jr., & Evan P. Phelps, DSHEA Provisions Conne FDA's Authority to Issue
Regulations that Concern Allegedly Adulterated Dietary Supplements, Food & Drug L.J. 595-598 (1999) and see 62 Fed. Reg.
30,678 (June 4, 1997).
61See id. 62 Fed. Reg. 30, 678 (June 4, 1997).
62See id.
63See supra Note 5.
64Adverse Event Reporting for Dietary Supplements: An Inadequate Safety Valve, Oce of the Inspector General, OEI-01-
00-00180, (April 2001) at www.dhhs.gov/oig/oei
11reason for this increasing portion of the population consuming dietary supplements is that they wish to take
an active role in their health. Some have become discouraged with prescriptions that failed to help them,
and therefore want to try a \healthier," \safer," more natural alternative.65 Today, dietary supplements
(including herbal therapies) are no longer shelved only at health food stores; they can be purchased at drug
and grocery stores.66 Drug companies and larger-scale manufacturers even eventually decided to cash in
on the dietary supplement craze.67 Due to the frenzy this proposal created by consumers and the dietary
supplement industry (a nearly $4 billion dollar industry that is growing at around 18 percent per year), and
due to the concerns voiced by Congress, the General Accounting Oce, and a directive from the Oce of
the Inspector General of the FDA's parent agency, the Department of Health and Human Services, the FDA
has backed down on this proposed regulation.68 The directive instructed the FDA to perform a complete
overhaul on its adverse reporting system. This requirement stemmed from a new report titled: \Adverse
Event Reporting for Dietary Supplements: An Inadequate Safety Valve" that found the current system wholly
inadequate.69 The FDA's Center for Food Safety and Applied Nutrition (CFSAN) has now redirected its
eorts from regulating ephedra to developing a broader strategy to address the problems.70
65See supra Note 17.
66Time for a Second Opinion, Harvard Health Letter, vol. 22, pg. 1 (November 1997).
67Ray Aragon, Will O'Brien, Suzan Onel, Dietary Supplement Makers, Sellers: Guard Against an Increase in Liability Suits,
Product Liability Law and Strategy, (April, 2000).
68See id. See also Jane E. Brody, Americans Gamble on Herbs as Medicine: With Few Regulations, No Guarantee of Quality,
N.Y. Times, at D1 (February 9, 1999).
69See id. See also Note 64.
70GMPS, Ephedra Still on FDA A List, Nutraceuticals International, (February 1, 2001).
12The Problem Still Exists, but is it a \Problem?"
So, how much ephedrine is in that bottle? Even if consumers become more aware and attempt to read labels
to avoid ingesting excessive amounts of ephedrine alkaloids, they may be making the eort in vein. A study
that measured the ephedra content of 20 ephedra products resulted in a fairly shocking outcome|half of
the products had an ephedra content that was 20 percent higher than stated on the label and one product
exhibited an enormous range of 1.8-10 times the amount depending on the lot.71 The growing conditions,
the plant's age, storage, handling, and preparation all play a role in the levels of an herb within a product.72
But the signicance of this information rests on the premise that ephedra isn't safe in these higher levels.
If it is indeed safe at higher levels for those individuals who do not have pre-existing medical conditions,
and safe for those who refrain from combining stimulants, it is possible that these variances are harmless.
Although, for those consumers who choose to vigilantly monitor their intake levels of ephedra because they
wish to use the product in conjunction with other medications, this could be fatal.
Products containing extraordinarily high doses of ephedra should be avoided (a bodybuilder taking 20 mg of
ephedra and 200 mg of caeine along with a creatine supplement containing 6,000 mg of ma haung (ephedra)
daily suered a stroke in Dec. 1999).73 The creatine supplement is extremely popular with bodybuilders
and it is important that the sports community receive information on the safety of such high levels of ma
huang.
71See supra Note 72.
72See id.
73Body Builder's Sudden Stroke May Be Linked to Ma Huang, Mealey's Emerging Drugs and Devices (January 7, 2000), (5
No. 1 MLREDD 24).
13Addressing Quality Control
A partial solution that has been suggested is for manufacturers to adopt the Good Manufacturing Practice
(GMP) standards required of over-the-counter pharmaceuticals, but this proposal seems to fall short of
reality and is not sucient to address the issue at hand.74 The most fraudulent companies producing
ephedra products are not likely to adopt these practices unless required to do so, and even then, compliance
of less than 100 percent would still leave the consumer vulnerable to choosing a product that does not use the
same standards. Some companies are currently abiding by the GMP standard.75 Of course, the label could
advertise the implementation of Good Manufacturing Practices, but this will not provide much information
to the average consumer.
Impetus for Self-Regulation
One incentive to adopt standards is the growing litigation over ephedra. When using dierent search engines
with the search term ephedra, a link to local legal help for ephedra adverse events is displayed rst. The
larger manufacturers and drug companies with deep pockets that now produce dietary supplements provide
a stronger incentive for lawyers to accept contingency cases of injured parties. Presently, class actions with
this herb are increasing. Recently, a class action suit was led in California against the dietary supplement
giant Metabolife and other smaller companies.76 The class seeks compensatory damages for neglecting to
74See supra Note 44.
75See supra Note 2.
76See supra Note 15.
14warn consumers about the possible eects of ephedra.77 Many settlements have already occurred regarding
ephedra, and lawsuits have increased with the growing coverage of this herb.78 Fortunately, and possibly as
a consequence of the increase in lawsuits, some companies have begun to work with the FDA to pull their
own products when notied of serious side eects.79 Other companies have added recommendations to their
product's label instructing consumers to consult a physician before using the product.80 (Although, until
physicians get up-to-speed with the dietary supplements, this may not be enough of an action to stave o
an adverse event.) The abundance and likelihood of ephedra lawsuits should encourage the industry and
individual companies to self-regulate in a more stringent and cautious manner.
Lawsuits not only involve failure to warn claims, but also include claims regarding impurity both for sub-
stituted ingredients and diering amounts of an ingredient than purported on the label.81 Suits against
trainers, nutritionists, health food stores, and diet counselors will also encourage that proper warnings are
given.82 A survey given to chain and independent pharmacists indicated that most pharmacists who would
recommend a standardized herbal formula over a non-standardized one did not understand the dierence
between them and did not have a good grasp of common uses of medicinal herbs.83
This startling information shows that a pharmacist could make a recommendation that a consumer would
trust despite the fact that the pharmacist has little knowledge about herbal remedies. People in trusted
positions must get up to speed with the latest information on herbal remedies. Even if the evidence is
inconclusive at the moment, the consumer should be made aware of the potential for interactions with other
herbs or medications and the fact that more is not better with herbs and can lead to serious injury. Lastly,
77See id.
78See supra Note 9.
79Rebecca Porter, Supplements Supply Dietary Danger, as FDA Looks on, Trial, (October 1, 1998).
80See supra Note 19.
81See supra Note 15.
82See id.
83See supra Note 43.
15doctors would not be immune from suit if they have failed to ask their patients what herbs or supplements
they are taking before prescribing medicine that could lead to an adverse interaction.84 A survey conducted
by the Beth Israel Deaconess Medical Center in Boston found that over 70 percent of patients did not inform
their doctors of the alternative therapies they used.85 This study furthers the idea that doctors should
have an armative duty to ask their patients what dietary supplements they take. With that responsibility
comes another{obviously the doctors must have some knowledge of dietary supplements or at least be willing
to look up the information. Information on dietary supplements is vast and confusing, which means that
current doctors will have to school themselves in this eld or go back to school. Medical schools such as
Harvard Medical School are beginning to address this issue by adding courses on alternative medicine to
their medical school curriculum.86
Safety
Manufacturers are quick to point out the fact that an herb such as ephedra has been used for centuries in
Chinese medicine. This type of advertising only fuels the perception that natural and herbal equals safe.
There is an implied test of time guarantee, but last tallied, there is a minimum of six wrongful death suits
against the manufacturer of Nature's Nutrition Formula One.87 The FDA has received more complaints
about ephedra than any other dietary supplement.88 In response to the complaints they received, the
FDA released a warning regarding this specic product and also gave out a hotline number for consumers to
84See supra Note 15.
85See supra Note 66.
86See id.
87See supra Note 35.
88See supra Note 2.
16call.89 This announcement was followed up by another one made on April 10, 1996 to healthcare professionals
requesting them to report adverse events to the FDA via Medwatch or the hotline.90
The question on the mind of everyone, including the FDA, is: Is ephedra safe for consumption? The jury is
still out on this question. One factor that increases the danger of ephedrine toxicity is its relatively short
half-life of six hours to ten hours{the levels of toxicity can be cumulative when it is ingested on a regular
basis, and the eect is heightened by other the use of other stimulants like caeine.91 Yet, the FDA has
itself approved the use of ephedrine in OTC drugs in dosages of 25 mg per use and up to 150 mg per day,
and declared that ephedrine is \generally recognized as safe and eective."92 This is quite telling because
synthetic ephedrine is stronger than ephedra. Pseudoephedrine was approved for single doses of 60 mg and
240 mg per day.93
The language contained within the Dietary Supplement Health and Education Act (DSHEA) also leads one
to believe in the safety of virtually all dietary supplements (\dietary supplements are safe within a broad
range of intake, and safety problems with the supplements are relatively rare").94 Adversaries of the FDA's
desire to regulate ephedra would provide statistics about the relative safety of ephedra versus prescription
drugs, and remind the reader that the causal link of most of the adverse events with ephedra has not
been established. Moreover, millions of doses of ephedra are taken each year by Americans without serious
repercussions.95 This illustrates that the herb can be safe if used as directed. This assertion is supported by
Dr. Mowrey's review of the FDA's AER list{he found that none of the serious adverse events had occurred
when the product when the product was ingested properly.96
89See supra Note 35.
90See id.
91See id.
92See supra www.ephedrafacts.com
93See id. www.ephedrafacts.com
94Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 108 Stat. 4325 (1994).
95See supra Note 13.
96See id.
17However, Dr. Mowrey also downplays the signicance or correlation of those who have died and their
consumption of ephedra. For example, he stated, Hundreds of people die in doctors oces while on treadmills.
Is it a surprise, then, that out of the millions of Americans using ma haung, one of them happens to experience
exercise-related injuries?97 There is logic in this statement, but the issue should also not be summarily
dismissed so quickly. It has become apparent that certain groups are at risk such as the 17-year-old high
school football player who reportedly never exceeded the recommended dosage and died of a heart attack
caused by ephedrine toxicity.98
Regardless of the problems with the reporting procedures used in the AEMS, one thing is clear: many of
those complaining of adverse events have misused or abused ephedra.99 During a testimony by Theodore M.
Farber, PhD, he explained that most people reporting negative eects \had hypertension, were diabetic, had
a family history of heart disease or were taking other medications|one person was taking 85 pills a day."100
It is certain that people with previous conditions including but not limited to heart conditions, elevated
blood pressure, asthma (and are on medication), diabetes, or glaucoma should not take this product.101 Or,
at a minimum, a doctor should be consulted.102
Unfortunately, sensitivities are impossible to predict for even healthy individuals.103 According to Anthony
Almada, president and chief science ocer of Imaginutrition, a natural products consulting group, 20 percent
of 100 people in a recent study on ephedra quit because they simply \couldn't handle ephedra."104 For
this reason, consulting a doctor even if you currently have no known health concerns would be wise. An
herb expert, Varro Tyler, PhD, strongly recommends people be supervised by a physician if they wish
97See supra Note 13.
98See supra Note 19.
99See supra Note 1.
100See id.
101See supra Note 1.
102See id.
103See id.
104See id.
18to use ephedra for longer than seven days.105 A doctor can aid in the prevention of a serious health
problem by monitoring the vital signs of the patient.106 For those who cannot aord this monitoring, serious
consideration should be given to the reasons for taking the herb and other stimulants should be avoided
completely. This herb is meant to provide initial assistance and not long-term aid for dieters.107 Some
experts believe that the long-term use of stimulants is not advised because they keep the body in a constant
'ght or ight' mode, rapidly depleting its energy reserves and potentially leading to a variety of disorders.108
More mild side eects like insomnia or headaches can also occur, which should provide alternative incentives
to avoid prolonged usage.109
Other healthcare professionals would argue vehemently against the assertion that the product cannot or
should not be used for a long-term diet aid. A six-month clinical trial study conducted at Columbia University
found that ephedra did aid participants in losing weight and increased their energy level.110 The patients
receiving ephedra lost twice the amount of weight the patients receiving a placebo lost.111 Nevertheless, long-
range studies need to be performed. Regardless of which camp you decide to join, it does seem evident that
until more extensive research is done, and until more thorough data can be compiled on the adverse eects
of the herb, a physician should be consulted for long-term use to ensure that the regimen is appropriate.
In fact, the Council for Responsible Nutrition sought to provide clarity on the topic by hiring a scientic
consulting rm, Cantox Health Sciences, to determine the safe dosage and overall safety of ephedra from
19 ephedra studies.112 According to council President, John Cordaro, The totality of information showed
a consistency that was compelling. They concluded that 90 mg doses per day were in fact safe for most
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19people.113 Those thought to be at risk and therefore should not take the ephedra are: anyone under 18,
people with heart disease, diabetes, glaucoma, high blood pressure, thyroid disease, kidney impairment, or
enlarged prostates, or pregnant or nursing women.114 The report recommends that the label reect these at
risk groups in the form of a warning.115
The results of this report were similar to another industry-sponsored study performed by Harvard and
Columbia.116 After glancing at the list of those in the at risk group, it is dicult to not worry about the
marketing and use of ephedra for weight loss in obese individuals. Many severely overweight individuals
would be the ones who would fall into the at risk category because they often have high blood pressure or
diabetes, which heightens the necessity to have these warnings placed on product labels. These reports help
to illuminate the safety question, and address the likelihood of adverse events in certain groups. Additional
studies are vital considering that the adverse eects are thought to be at least tenfold the number the FDA
has recorded.117
German Commission E Monographs
The German Commission E was founded in 1978.118 On January 17, 1991, they published a monograph on
ephedra.119 One reason for the creation of this commission is that herbal medicines account for 30 percent
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20of the drugs sold in pharmacies there.120 Herbs require the E marking to be on the market.121 A critical
dierence is that over half of the herbs are actually prescribed by physicians.122 A 1997 poll on the use of
herbal medicines showed that two-thirds of those polled took herbal medicines and of these two-thirds, 72
percent had a minimum of some college education.123 The phytopharmaceutical companies sponsored the
testing of ephedra's toxicity, which is possibly the reason that the toxic eects are less comprehensive in this
report than in The Laurence Review of Natural Products.124
The German Commission E lists the uses, contraindications, side eects, interactions with other drugs, rec-
ommended dosages, mode and duration of administration for ephedra.125 Interestingly, weight management
and increased energy are not included in uses.126 Furthermore, the potential for fatal eects is absent.127
Strangely, under higher dosages, development of dependency is listed.128 Interactions with other drugs in-
clude: cardiac glycosides or halothane, which results in the disturbance of the heart rhythm; guanethidine
and MAO-inhibitors, which lead to an enhancement of the sympathomimetic action of ephedrine; and nally,
decale alkaloid derivatives or oxytocin, which can cause the development of hypertension.129 Adult dosage
is set at 15-30 mg per dose with a daily maximum of 300 mg.130 Children are limited to.5 mg of total
ephedrine alkaloid per kg of body weight with a daily maximum of 2 mg of total ephedrine alkaloid per kg
of body weight.131 The duration of administration states that this herb is for short-term use only because
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21of tachyphylaxis and danger of addiction.132
In a note, the International Olympic Committee and the German Sports Association have qualied ephedra
as addictive.133 However, Edgar H. Adams, M.S., Sc.D., former Director of the Division of Epidemiology
and Statistical Analysis at the U.S. National Institute on Drug Abuse, provides a more current evaluation
of ephedra.134 He found no reason to believe that this herb possesses addictive qualities.135 Although, he
did not categorically rule out the possibility, he did state that the likelihood was low and not certain enough
to merit regulatory control.136
It was the American Botanical Council (ABC) that made the highly anticipated English translation avail-
able.137 Well-respected professionals such as Professor Varro Tyler and Dr. Andrew Weil touted this pub-
lication as oering the most accurate information in the world{a reference guide that doctors can trust.138
But, the monographs in this guide are incredibly brief with very little detail.139 In fact, references to liter-
ature are conspicuously absent, which diminishes their value as a complete resource because the rationale
for the decisions made is not ascertainable.140 Regarding this aw, Professor Heinz Schilcher, the Vice
President of the Commission, divulged that speculation rather than scientic data is sometimes used to
reach some conclusions that appear in the monographs.141 This is disconcerting when the monographs have
received such acclaim and praise for being the most scientic and trustworthy source of information on
herbs.142 Some physicians and pharmacists have begun to cite Commission E monographs as immutable
truths, which is cause for alarm when it is known that the monographs do contain some mistakes, omissions,
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22and speculations.143
The recommended dosages may also present a problem when applied in the United States.144 For example,
the ephedra dosages are listed for the preparation of the dried herb for German aqueous infusions or decoc-
tions, but in the United States the hydroethanolic extracts are usually taken from fresh and not dried herbs,
and the conversion needed can be complex.145 Similarly, the use of standardized herbal material, occurring
more frequently, makes the task of correlating the standardized herbal material to the infusion based dose
data in the monographs more dicult.146 Another topic of concern relating to the monographs and the
ephedra monograph specically, is the lack of available studies at the time.147 This could drastically impact
the recommendations the Commission made.148
In spite of the aws contained in the German Commission E Monographs, the American Botanical Council
believes that the Commission E system can provide an excellent model for regulatory reform, in the United
States and possibly other countries, by providing a rational process for reviewing herbs and phytomedicines
for their safety and ecacy.149 Naturally, ABC has an incentive in pushing the authoritative nature of this
work.150 It can add to the credibility of the use of herbs for medicinal purposes, which aids in solidifying
their role as intermediary between the industry, physicians, and the FDA.151 It is valuable to avoid over-
inating the worth of this publication because it should not be the only source consulted, nor should the
herbal industry be lulled into thinking that further substantial eorts in creating more useful and detailed
monographs is not a priority. Nevertheless, the German Commission E monographs are a starting point that
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23we can learn from and improve upon.
The History of Dietary Supplement Regulation
Some senators remarked that the lobbying eorts for the Dietary Supplement Health and Education Act
(DSHEA) paralleled the Vietnam War.152 \Many members of the House of Representatives and Senate
stated that they were receiving more mail, more phone calls, and generally more constituent pressure on
this subject than on anything else|including health care reform, abortion, or the decit."153 At that time,
there was a commonly held belief that the FDA was regulating the dietary supplement with an iron st.
Consumers wanted access to herbs and supplements without being forced to wait for FDA approval. The
combination of the mass campaign and the underlying argument that health of Americans should be a
priority and that the \importance of nutrition and the benets of dietary supplements to health promotion
and disease prevention have been documented increasingly in scientic studies."154
As a result, DSHEA was passed and was signed into law by the President on October 25, 1994, but took eect
in 1996. This was a watershed event for the dietary supplement industry and consumers of their products.
The amendment was enacted to appease the American public and the dietary industry and to ensure the
availability of products that are accurately labeled and safe.155 The language of the statute even indicated
that the FDA had taken on too much of a big brother role in regulating dietary supplements. This is evidenced
in the warning sentence: \the Federal Government should not take any actions to impose unreasonable
152See supra Note 41.
153See id.
154Stephen H. McNamara, FDA Regulation of Ingredients in Dietary Supplements After Passage of the Dietary Supplement
Health and Education Act of 1994: An Update, 51 FOOD & DRUG L.J. 313 (1996).
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24regulatory barriers limiting or slowing the ow of safe products and accurate information to consumers."
President Clinton's statement to the public upon signing the legislation reected this sentiment.156 He
declared that the FDA had complicated the decisions consumers needed to make and \paradoxically limited
the information to make healthful choices."157
This Act basically amended the portion of the Federal Food, Drug, and Cosmetic Act (FDCA) dealing with
dietary supplements and their dietary ingredients.158 Herbs fell under the rubric of dietary supplements
because DSHEA dened a dietary supplement as product meant to supplement the diet that contained
herbs or other botanical substances, amino acids, vitamins or minerals, or a combination of these.159 Prior
to DSHEA, dietary supplement companies were required to pass the \new drug approval" (NDA) process,
which included submitting pre-market evaluations on the safety and ecacy of the new product, and the FDA
was able to determine whether the labels were misleading or easily understandable.160 Most herbs never
made it through the NDA process, which was partially due to the fact that companies had no incentive
to spend substantial amounts of capital on the research for the required safety and ecacy substantiation
because herbs cannot be patented.161 Under DSHEA, this pre-market approval information was no longer
necessary and the barrier to market entry was removed.162 A safe harbor was created for companies to
manufacture herbal remedies that would be classied as dietary supplements.163 This classication blocks
the FDA from regulating the herbal products as food additives, which would have given them more regulatory
authority.164
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25DSHEA dramatically aected labeling of dietary supplement products. It requires that products be clearly
labeled as dietary supplements, and have the name and quantity of each ingredient on the label.165 If it is
a combination product, the label must list the total amount of non-inert ingredients.166 An herbal product
must state the specic part of the plant from which it was derived.167 Nutrition information in order of most
signicant amounts for which the FDA has established guidelines is also required. Section six of DSHEA has
had the greatest impact on the dietary supplement industry's ability to market their products. It enabled
manufacturers of herbal products to make structure-function claims on the packing of their products.168
Section six denes when a statement is acceptable: \The statement claims a benet related to a classical
nutrient deciency disease and discloses the prevalence of such disease in the United States, describes the
role of a nutrient or dietary ingredient intended to aect the structure or function in humans, characterizes
the documented mechanism by which a nutrient or dietary ingredient acts to maintain such structure or
function, or describes general well-being from consumption of a nutrient or dietary ingredients."169
For example, a company producing Valerian cannot state that the product cures insomnia, but it can refer
to the products' ability to \promote restful sleep" provided that it also includes a disclaimer that \this
statement has not been evaluated by the Food and Drug Administration. This product is not meant to
diagnose, treat, cure, or prevent any disease."170 This tacked on statement does not suciently indicate
that the consumer should be cautious. As evidenced by the example above, the structure/function claims
can be misleading and certainly the average or even above average consumer is not knowledgeable about
the blurred demarcation and will not think critically about the fact that the claim does not armatively
proclaim to cure insomnia. Consequently, the structure/function claim standard, third-party marketing
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26materials, and statements such as this product has recognized healing properties has fueled the natural
equals safe perception and enhanced consumers unquestioning belief in the ecacy of the products.171
In February of 1996, the appointed Commission on Dietary Supplement Labels (a commission provided for in
DSHEA) had their rst meeting.172 In a 1997 report, they suggested that dietary supplement manufacturers
should bear the burden of self-regulation in regards to the warning labels and safety of their products.173 The
commission has advised against misleading consumers with product labels, and has suggested that unveried
claims should be blatantly qualied.174 They also strongly advised the industry to provide unbiased material
on the products that addresses evidence of nutritional support, product safety for its intended use, and
safety of dosages.175 While these are all useful suggestions, it is the implementation and incentive for
implementation that has been lacking.
DSHEA also aected the FDA's ability to establish a case that a product was in fact a new drug by banning
the use of advertisement claims of products in publications associated with the sale of supplements in order
to aid in demonstrating improper labeling.176 These publications could not be attached to the product
directly, push a specic brand or manufacturer, be false or misleading, and the publication needed to oer a
balanced presentation of the available scientic information.177 And, once again, the FDA bears the burden
of substantiating any infraction of this provision.178 The consequence of this section of DSHEA is an ability
on the part of manufacturers of dietary supplements to make claims and representations that could not
otherwise be made. These publications have aided in the perception that dietary supplements are safe and
certain herbs or supplements can be a panacea.
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27DSHEA does provide two methods of regulation as long as a dietary supplement or an ingredient qualies
as adulterated.179 In order to fall under this provision, the supplement or ingredient must \present a
signicant or unreasonable risk of illness or injury under conditions of use recommended or suggested in the
labeling, or if no condition of use are suggested or recommended in the labeling, under ordinary conditions
of use."180 Essentially, the supplement or ingredient must place the public in a position of signicant risk
for imminent harm.181 The United States bears the burden of proof of establishing the above conditions.182
More importantly, if the FDA were to attempt to enforce a new regulation regarding a dietary supplement,
the FDA would still be forced to demonstrate the dietary supplement was adulterated.183 Basically, dietary
supplements are regulated as foods.184 Companies manufacturing herbal products do not have to conform
to a standard dosage or strength.185 As a result, the FDA has been placed in position of regulating by news
release.186
The Flaws of the FDA's Collection of Adverse Event Reports
Because the FDA cannot regulate dietary supplements as drugs, it is relegated to a watch and wait position.
It needs to provide conclusive evidence that a product is unsafe for consumption before it can ban or remove
a dietary supplement from the market.187 It is for this reason that the eectiveness of collecting information
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28on the safety of dietary supplements is imperative. The FDA's Adverse Event Monitoring System (AEMS)
was designed to aid them in assessing hazards connected to specic dietary supplements and alerting the
public of any safety issues with these products.188 The AEMS was designed to \1.detect adverse events,
2.generate signals of possible public health concerns, 3.assess those signals, and 4.take appropriate safety
actions based on its assessment."189 One large fault of the reporting system is that the adverse event may or
may not be associated with the injury because conrmation is not guaranteed.190 Moreover, the reporting
of an event is not compulsory, so it is unclear how many other adverse events are occurring from ephedra.191
One company has admitted to receiving 3,500 consumer complaints that were never reported to the FDA.192
Based on the FDA's conclusion of the risk posed to the public (experts and/or studies are used to determine
this), the FDA will issue warnings, alerts, request a product recall, or seize a product.193 Because the results
of AEMS for ephedra led the FDA to propose a new regulation to limit the amount of ephedrine alkaloids
within a product, the aws of the AEMS are crucial to this validity or necessity of this proposal. Due to
strong criticism, the FDA has since withdrawn this controversial proposal.194
A recent study commissioned by the FDA found that the FDA receives reports on under one percent of
the actual adverse events that occur, which is thought to be a result of the consumers' belief that natural
equals safe, the fact that these products are used without a doctor's supervision, and because consumers
are not aware they should contact the FDA.195 Many consumers contact the company instead, and the
company certainly has no incentive to report adverse incidents to the FDA|quite to the contrary, doing so
could negatively impact their nancial earnings. Unless the company is aware of a deadly result or serious
188See supra Note 186.
189See id.
190See id.
191See id.
192FDA to Consumers: Good Luck with the Dietary Supplements, vol. 23, pg.1 (January 1, 2001).
193See supra Note 186.
194Under Examination, Medical Malpractice L. & Strategy, (April 12, 2000) (17 No. 6 MEDMALLST 12).
195See supra Note 186.
29deviation in their formula causing serious bodily injury, they are not likely to contact the FDA (if such a
serious outcome were likely, they would be motivated to make every possible attempt to correct the problem
in order to avoid class action and individual suits that could leave them bankrupt).
Missing data is another obstacle in the way of validly interpreting the safety of particular dietary supplements.
The FDA lacks the medical records tied to the events reported, which is in part due to the fact that only
20 percent of adverse event reports originate from a doctor.196 It also has inadequate information on the
products consumers or doctors cite as the cause of their symptoms.197 Surprisingly, the FDA is unaware of
the ingredients contained in 32 percent of the reported problematic products, does not have the labels of 77
percent of the \problem" products, and had not obtained samples for 69 percent of the reported products.198
Other substantial aws include the inability to ascertain the manufacturer for 32 percent of the products,
and the inability to follow-up with callers agged for follow-up due to inadequate contact information.199
All the aforementioned defects leave the FDA incapable of analyzing the data in a meaningful way.200
This relates directly to their ability to establish a connection between the reports and the safety of the
products. At this point, the FDA does not have enough clinical information on the dietary supplements
on the market because it is not required of the manufacturers (there is an exception that aects a small
number of manufactures|certain new dietary ingredients must submit \relevant" safety information 75 days
prior to market introduction), but more clinical information is becoming available on almost a daily basis.201
Another essential missing data point is the total number of consumers who take a specic product.202
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30The lack of comprehensive data necessarily leads to inaction on the part of the FDA. Any action taken would
be attacked severely, which is evidenced by the proposed regulation to limit the allowed dosage of ephedra.
Instead, the FDA has relied on its website to inform the public, but this site is inadequate because it is
not updated regularly, and according to the report by the Oce of the Inspector General (OIG), the site
\contains misleading information."203 Because consumers need to be informed, changes must be made to
the adverse event monitoring system. The present system has very little scientic value because of the gaps
of information and lack of follow-up data. Therefore, the OIG has published a report on the AEMS and
made recommendations for the FDA to follow.
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31OIG Recommendations for the FDA
OIG determined that the entire framework of the AEMS requires
modication and some legislative or regulatory alterations will be
necessary in addition to more funding to execute the changes.204
The FDA has responded positively to the suggestions by listing
many of them as their top priorities for the year and in their 10-
year strategic plan for
dietary supplements.205 I have included the majority of the infor-
mation from the report because of its relevance to the future of the
FDA's treatment of ephedra. Moreover,
because the report was only released in April, it has not received
extensive written treatment.
A.
Recommendation One: \Facilitate greater detection of adverse events."206
i.
Demand that manufacturers of supplements notify the FDA of any
serious adverse eects for certain products.207 This recommendation will force the FDA
to draw a bright line for products or ingredients that will be subject to this requirement.
ii. Establish a contract with the Poison Control Centers to have access to their adverse event reports on
dietary supplements.208 These reports will provide useful safety data.
iii. Provide information to professionals in the healthcare industry and consumers about the AEMS for
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32dietary supplements.209 One suggestion for implementation of this recommendation was to require manufac-
turers to include their own toll-free number or the toll-free number of the FDA, and to enlarge the program
for informing doctors of current information on dietary supplements.210
B.
Recommendation 2: \Obtain more information on adverse event reports in order to
generate stronger signals of public health concerns."211
i.
Promote educational programs for increased understanding within
the health professional's community on how essential the inclusion of medical infor-
mation in adverse event reports is.212 This information will enable the FDA to more
eectively draw conclusions about the safety of the supplement.
ii. Make it mandatory that dietary supplement manufacturers register their products with the FDA.213
This would be one of the most useful, yet dicult recommendations to implement. This would address their
inability to discern the manufacturers of products in question.
iii. Demand that dietary supplement manufacturers register with the FDA.214
iv. Communicate serious adverse event reports to manufacturers upon receiving them at the FDA.215 This
would allow the manufacturers to address the problem as quickly as possible if it was deemed necessary after
further testing.
v. Relay the signicance of self-identication to health professionals and consumers.216 This ensures that
the FDA can gather any necessary follow-up information.
vi. Acquire a new computer system that will track and analyze adverse event reports.217 This would give
the FDA the ability to slice-and-dice the information within the database based upon the desired information.
C.
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33Recommendation 3: \Obtain vital information to adequately assess signals generated by
the adverse event reporting system."218
i.
Provide more direction regarding the specic safety information
desired by the manufacturers who currently are required to submit a 75-day pre-market
notication for new dietary supplement ingredients.219 This is already within the
sphere of FDA control, and therefore, the FDA shouldn't waste a low cost opportunity
to gain more information.
ii. Look into the option of a monograph system for dietary supplements, which is a system that details
that details ecacy and safety information on certain ingredients.220
iii. Work with the National Institutes of Health in order to agree upon and establish an agenda to target
safety concerns.221
iv. Help the industry and the United State Pharmacopoeia to implement standardization with supplement
ingredients, namely botanicals.222
v. Facilitate the rapid development and execution of Good Manufacturing Practices for manufacturers of
dietary supplements.223 This would necessary for implementation of the standardization of ingredients.224
D.
Recommendation 4: \Disclose more useful information to the public about dietary supple-
ment adverse events."225
i.
More useful and up-to-date information is needed on the FDA
website.
ii. Summarize reported data in order to discern causation.
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34Response from the Trade Associations
The trade associations reviewed the report and oered three main criticisms: 1. the report does not attempt
to address the internal operating procedures of the FDA's AEMS, 2. the report did not take DSHEA into
consideration in the recommendations section, and 3. it did fail to factor the desire of the public to have
control over/access to their \self-care" products.226 All these concerns have merit, yet it is clear that change
needs to occur within the AEMS. It is now a matter of developing the most practical, cost-eective, and
useful solution.
The Consumer Healthcare Products Association (CHPA) has led a consortium of dietary supplement trade
groups to join forces in an eort to work together to petition the FDA to enforce a nationally standardized
formulation, labeling, and marketing of ephedra.227 They have requested synthetic ingredients and unlawful
claims to be vigilantly monitored and swiftly acted upon.228 They have stressed that action against com-
panies engaging in fraudulent practices be taken because those companies have a detrimental eect on the
compliant companies.229 CRN would also like to see more publicity regarding the new, more active enforce-
ment the FDA plans to initiate in hopes of deterring companies from carrying out fraudulent plans.230 The
companies currently participating in self-imposed standardization does not denitively qualify the product
as safe.231 Additional research is needed to determine safe and eective levels of ephedra. Until more studies
are done, caution should still be exercised with this product, but standardization is a move in a positive
direction.
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35Threat to Prescription & Non-Prescription Pharmaceutical Weight Loss Industry
Some are pointing the nger at the prescription and non-prescription pharmaceutical weight loss industry for
wielding their power and inuence to sway the FDA to regulate, as increased regulation will help ensure their
protability. Products containing ephedra are competing with their brands and aecting their market share.
Recently, the dietary supplement industry pushed for legislation that would prevent states from banning
ephedra and other herbal products.232 This bill is titled the National Food Uniformity Act of 2000.233
States Respond by Regulating Ephedra
At least 17 states (Arizona, Arkansas, California, Florida, Hawaii, Idaho, Louisiana, Missouri, Nebraska,
Nevada, New Mexico, Ohio, Oklahoma, Oregon, Tennessee, Texas, and Virginia) now have passed some
form of legislation restricting the sale of ephedrine based products.234 Some states have been much tougher
on ephedra than others. For example, Ohio has classied products containing ephedrine as schedule V
controlled substances.235 Schedule V restrictions require that the supplement be dispensed by a pharmacist
in amounts no greater than 100 in any 30 day period.236 Purchasers must be 18 years of age with valid
identication, and they must give their address and signature.237 Florida has made ephedra available by
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36prescription only, and has limited the claims allowed on packaging.238
To Regulate or Not to Regulate
Do we want to restrict the freedom of millions just to protect the health of a few foolish zealots?239 Some
would answer this question with a resounding yes. The FDA has been in a dicult position and is often
accused of doing nothing or attempting to do too much.
Ephedra may be useful in reducing total obesity related medical costs. Even a 5-10 percent decrease in
weight can lead to enormous medical benets, such as improvements in blood pressure, lipids, and blood
glucose, as well as a rise in self-esteem and a lowering of depression.240 The immediate key to avoiding the
serious injuries is education. Many overweight consumers are so desperate to lose weight that they increase
their intake of the ephedra. For example, one woman consumed over 28,000 mg of ephedra per day, which
led to acute paranoid psychosis.241 Consumers need to know and understand the risks they are taking with
ephedra.
Ephedra is an herb that mimics the eects of drugs requiring a prescription, but it is regulated as a food.
An attorney who handled an ephedrine case in Florida remarked that if an herb has the same physiological
eect on the body as a synthetically produced version, it ought to be regulated (if it acts like a drug, it
should be tested and regulated like a drug).242 Perhaps strict regulation is not the answer and would run
counter to the intent of Congress as memorialized in DSHEA. There may be other alternatives to regulation
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37or another form of regulation that would not hamper companies from producing safe and healthy products
that consumers want access to.
At least for the moment, the industry and consumers alike can rest easy because of CFSAN's decision to focus
on creating strategy to address the problems with the adverse event reports rather than propose regulations.
Their goal in regards to the AEMS is to create a system that makes adverse event reports promptly available
to manufacturers that includes the timely redaction of condential information and allows for follow-up
investigations and clinical assessments.243 The president of a Washington, D.C.-based trade association,
Council for Responsible Nutrition, that represents a large portion of the ingredient suppliers and nished
product manufacturers, stated that the FDA needed to hone their agenda.244 The US General Accounting
Oce oered the same criticism.245 In its present form, the plan is not actionable because it is too broad in
scope and doesn't provide a detailed plan to facilitate change.246
As of April 2000, the FDA began to consider a new proposal to ban any products that combine ephedra and
other stimulants.247 Given the current conicting and paltry research available on the interaction eects
of ephedra, it seems that any proposal limiting the combinations in question would be premature. At this
point, it would appear more sensible to focus on nding a way to regulate the unsafe products produced by
companies that are inadequately or falsely labeled, or have patently questionable amounts of ingredients.
Realistically, any drastic regulatory solutions will be met with such a powerful opposition from the industry
and consumers that the proposals would stand slim chance if any of becoming nal rules, as witnessed
with the FDA's recent short-lived proposal to restrict the use of ephedra. Signicant public outcry will
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38be necessary to amend DSHEA. According to a recent study completed by National Public Radio, the
Kaiser Foundation, and the Kennedy School of Government, consumers are in fact now wanting stepped up
governmental regulation for dietary supplements to ensure purity and safety, and to qualify the veracity of
health claims made in advertisements and on labels.248 It may just be a matter of time before the pendulum
swings back toward the direction of greater regulation, especially if that regulatory scheme will allow access
to products without reducing the information consumers seek.
Until the backlash occurs, the FTC can play a more extensive role in the regulation of dietary supplements.
While DSHEA left the FDA with substantially less authority to regulate the dietary supplement industry, the
FTC has maintained its ability to challenge the health claims and deceptive advertising of manufacturers.249
Manufacturers must demonstrate a reasonable basis for the claims and/or advertising, which translates into
competent and reliable scientic evidence from objective studies conducted by experts.250 However, the FTC
cannot require a company to test the product to ensure it is safe at the recommended dose, nor can it force
a company to include a warning about harmful side eects.251 Nevertheless, the FTC has been somewhat
successful in their regulation attempts (both in court and with administrative orders), but they could be
more vigilant in their policing eorts, which would aid both the FDA and the American public.252
While stepped up eorts by the FTC will be helpful, the FTC alone can not rectify the situation. Dr.
Mowrey testied before the House Government Reform Committee that he believes the answer may lie in
a new regulatory category such as medicinal foods.253 Another suggestion was the creation of a category
called traditional herbal therapies.254 This idea has merit because the FDA would not be forced to impose a
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39pre-existing and ill-tting structure upon dietary supplements. It is possible that a new regulatory category
could work in the future if it took into consideration the constraints of the dietary supplement industry
regarding scientic proof and did not deny consumers access to products based on insucient safety data.
A new category should at least tackle the current problems with misleading labeling and should begin to
address the task of collecting more scientic data on these dietary supplements in order to better ascertain
the safety and proper dosages and interactions of the supplements. However, even this proposal would meet
strong objections from the industry stemming from a fear of a reduction of control. For this reason, the
immediate focus should be on aecting change that is possible within the immediate future.
FDA Action Plan
Despite the FDA's plans for change, trade associations and the GPO have criticized the lack of denite
deadlines for execution. In defense of the FDA, without the allocation of funds for this project, it is not
possible to implement all the changes and any deadlines would be knowingly unattainable. Funding from
Congress must be increased if the FDA is to carry out its responsibilities eectively. Critics of the FDA such
as Senator Orrin Hatch and Representative Bill Richardson, agree that greater consumer knowledge about
preventative medicine should be encouraged, yet more funding is a prerequisite for this to occur.255
Guidelines
FDA guidelines are an alternative to regulation that is realizable without immense cost or long delays.
The guidelines could be updated once comprehensive studies are performed, but until then, the available
assembled data could be used. The updates to the guidelines could be implemented eciently because they
255See supra Note 2.
40do not have the force and eect of law and accordingly would not have to go through the same channels
as regulations. This allows the FDA to abide by DSHEA and the intent of Congress, and does not require
the substantial additional funding or delays that many other options would. The guideline could signify the
position of the FDA and be used in court to establish the FDA's views regarding the issue at hand. The FDA
policy on guidelines allows the FDA to establish principles or practices of general applicability that relate to
performance characteristics,...product standards,...compliance criteria,...and ingredient specications.256
According to FDA procedures, the Center director would possess the authority to change the guidelines.257
Good Manufacturing Processes
Another initiative the FDA can take that does not require funding that can assist in moving forward on
improving the safety of dietary supplements involves good manufacturing processes (GMPs). More than ve
years ago, an assembly of industry groups drafted a standard for GMPs, but the FDA has yet to publish a
nal rule on this proposal.258 Approximately 90 percent of manufacturers use the warning label that was
created for ephedra, but there are still enough companies in existence that do not that can cause harm to
the public.259 This requirement alone will not suciently address the major issues with the regulation of
dietary supplements, but because the solution will involve several minor and major changes, each eort will
move the FDA and the industry closer to that goal.
Reallocating Responsibility
One way in which the FDA has already attempted to aect change without additional sources of funding
from Congress is through redistributing task responsibility between two dierent centers under the FDA in
order to increase eciency and accuracy. This action has come under re by trade associations.260 The
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41Center for Drug Evaluation and Research (CDER) will now be responsible for determining whether product
labels purport to cure diseases.261 This decision has troubled CRN and other trade associations because
they fear that such a move brings dietary supplements closer to being regulated as a drug.262 The trade
associations argue that DSHEA made it clear that dietary supplements should be regulated as foods, and
therefore should be under the control of CFSAN.263 But this argument does not take into consideration the
lack of funding.264 The FDA needs additional funding to carry out the plans to change their current system.
If the FDA can get another one of their centers to assist in the problem with clearly dened instructions
that would comply with DSHEA, it seems that the associations' complaints are without merit. Ideally, the
FDA would be able to establish a center or committee dedicated only to the dietary supplement industry.
Labeling
The change involving CDER follows in the wake of the Pearson v. Shalala decision in which the court held
that particular health claims were protected by the First Amendment.265 The court of appeals disagreed
with the FDA's argument that certain health claims are inherently misleading and can be disallowed on that
basis.266 In fact, the court remarked that this contention is almost frivolous.267 Furthermore, the court
held that the standard of signicant scientic agreement was far too vague and needed to be claried.268
More disturbing was the risk assessment the court performed. It did not consider the fact that risks are
relative and serious adverse events have been documented.269 There is risk with many drugs, but at least
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42there is quantiable benet.270 With dietary supplements, the risks and benets are not well understood.271
Unlike the district court, the court of appeals framed the issue primarily around First Amendment rights
rather than on the governmental interest of protecting the health and safety of the public.272 However, the
court of appeals did not seem to take into consideration that the Supreme Court has asserted that the First
Amendment does not prevent the government from ensuring that the stream of commercial information ows
cleanly as well as freely.273 The court of appeals did not agree that disclaimers and warnings are insucient
to solve the problem of consumer deception.274 This case demonstrates the complex issues and diculties
dietary supplements pose in terms of regulation.
The industry is anxiously waiting to see how the decision will be implemented.275 Labeling is a thorn in
the side both the FDA and the industry. Many fear that the FDA will create two dierent types of claims
under the Nutrition Labeling and Education Act (NLEA).276 One type would be approved as truthful and
not misleading without the need for disclaimers, while the other would be approved only with disclaimers.277
Naturally the trade wants to ensure as much control and freedom over labeling as possible. Another possible
result of this decision is that drug manufacturers may attempt to spare the costly expense of clearing the
hurdles drugs must meet, and instead use herbal forms of the substance when possible in order to get the
product to market faster and with fewer restrictions.278 In the meantime, until comprehensive studies are
completed, requiring an additional statement that is prominently placed in bold on the package that states
DO NOT MIX THIS SUPPLEMENT WITH ANY PRESCRIPTION MEDICATION WITHOUT THE
ADVICE OF YOUR PHYSICIAN, AT THE RISK OF SERIOUS INJURY would possibly be an eective
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43method to prevent unnecessary adverse events.279 This statement on packaging brings the FDA closer to
achieving its goal of increased public awareness.
Education and Awareness
Educating the public by disseminating information on ephedra should be one of the rst tactics to try to
combat this extremely misunderstood herb. This will serve to correct the problematic and faulty equation
most people subscribe to so that eventually the general public will come to realize that natural does not
equal safe. Such an approach should also notify consumers to be savvy in their dietary supplement purchases.
Consumers must be instructed to be more aware that labels need to be read because in many instances, they
have no idea they are taking the herb.280
Eorts have been made on the part of the FDA and the FTC to inform the public, but the messages are
not reaching a broad enough audience. The FDA has a newsletter that uncovers many top health frauds,
while the FTC also has publications to inform the public on how to identify fraudulent claims.281 The
FTC has advised the public to be cautious to avoid falling into the trap of thinking natural equals safe,
but what percentage of the public received this message? Clearly, the message needs to be more eectively
broadcast. Both the FDA and the FTC have websites brimming with useful information that the public has
access to. The problem seems to be a lack of consumer awareness about the sites and materials published.
Many consumers either lack the resourcefulness necessary to nd the information, or the time to seek it out.
Therefore, the information is not achieving the maximum potential impact it otherwise could have. The
message must be delivered to the public in such a way that it is likely to be received.
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44An unusual possibility, television advertisements, requires more funding, but it would be money well spent
because it would bring the FDA and FTC closer to their goals of protecting the public through education
and at a minimum, awareness. Placing announcements on the big screen before the trailers begin in a
theater would be another opportunity to feature information in a manner that will reach the intended
audience. There is an overwhelming amount of contradictory evidence available making it impossible for
most consumers to come to a conclusion in which they feel certain. But, most consumers never bother to
investigate due to time constraints or a lack of knowledge as to where to begin their search. Instead, most
purchasers of dietary supplements get their information from friends, labels, or sales people.282 Perhaps
using mainstream media is unconventional, but the traditional approaches are not eective. Thinking out of
the box will push change further and faster than contained thinking. It may require more eort and creative
problem solving skills than prior methods, but improvement in awareness is well worth taking some risks.
Getting the information out is necessary to counteract the role models such as Mark McGwire who has
accredited part of his achievement to ephedra products.283 Even coaches and parents have encouraged their
athletes to ingest these wonder pills for a better performance and physique.284 For this target category,
another appropriate forum for dietary supplement education is the public schools.
In conjunction with the distribution of information, the medical community needs to be better educated
in the eld of herbal medicine. Even though many schools are adding courses in alternative medicine to
the classes they oer, and doctors may attend them, they are not required to. A program similar to the
CLE course mandatory for lawyers would remedy this gap created by the exploding consumer use of herbal
medicines.
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45Formation of Alliances
It may be wise to form alliances with other organization to deliver the messages to the public. Groups
such as Halt Ephedrine Abuse Today (H.E.A.T.) would be a natural choice regarding this specic dietary
supplement. This non-prot organization was born after the death of the founding mother's 24 year-old
son who died from ephedrine toxicity.285 Their stated mission is: to increase public awareness about the
dangers of ephedra and to promote the prevention of abuse of ephedrine.286 Other groups such as the
American Heart Association, the Herb Research Foundation, the Alliance for Alternatives in Healthcare, the
American Herbal Products Association, and the Alternative Medical Association are but a few additional
examples of groups that should be contacted to join in this informational alliance. They all have in interest
in making sure that the public does not misuse products that can lead to serious side eects. Moreover,
they also have an interest in making sure that the public is made aware of any scientic substantiation of
natural products. This idea of alliance creation has begun, but needs to continue. On May 14, 2001, the
National Center for Complementary and Alternative Medicine (NCCAM) at the NIH arranged a colloquium
to explore opportunities to collaborate with two key groups (industrial stakeholders who produce and label
dietary supplements, and organizations that develop and apply standards to determine the quality and safety
of these products) as well as many other groups (federal regulators, consumers, practitioners of all types,
researchers, publishers, etc.).287 This eort demonstrates the perceived value and necessity of such alliances.
The alliances have the potential to be instrumental in redesigning the adverse event monitoring system. For
this reason, before making changes to the system, the FDA should assemble representation from the industry
in order to create the most eective system. Secondly, funding for the computer systems and personnel to
analyze the data must be considered.288 These systems are crucial to the understanding and documentation
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46of the side eects of dietary supplements. If the systems and processes are inadequate then the data collected
has little to no scientic value.
Mandatory Contribution from the Industry
A more controversial solution that is sure to be met with erce opposition from dietary supplement manufac-
turers is a requirement that would make the industry responsible for funding the necessary scientic studies
that are at the epicenter of the controversy over the safety and ecacy of these dietary supplements. Each
company could be required to donate a percentage of their prots for the studies, provided they produce
a product with the targeted ingredient. DSHEA lifted their burden of proof and opened the door to a
thriving fraudulent sector of the industry. Using the German Commission E, the Physician's Desk Reference
for Herbal Medicines, the National Center for Complementary and Alternative Medicine, and the database
begun by the Oce of Dietary Supplements at NIH is a decent beginning point for these studies in the eort
to create more accurate and thorough monographs.289 These monographs can lend credibility to the use of
dietary supplements, which have the added eect of making patients more comfortable with informing their
physicians of their use of dietary supplements.
This nancial burden would not restrict the current sales, marketing or production in place, but would
ensure more accurate information is ascertained as to the appropriate dosages, dangerous interactions, and
benets of the supplement. If in fact a supplement is found to be dangerous or toxic to the user in its present
form, then the FDA could act on this information. If the supplements are as safe and eective as they claim
to be, the industry should have no contention over such a plan{except for the gouge it will make in their
protability and a concern for the methodology of the testing. Alternatively, if the FDA could not gain
the support necessary to require this measure, they should request additional funds to be able to lessen the
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47nancial burden on companies.
Rating System
A rating system could be implemented to tackle the problem of scientic agreement or substantiation.290
The scale could rate herbs on a 1-5 basis for eectiveness.291 For example, if only anecdotal exists, the
product would receive a rating of 1, whereas a 5 could inform the consumer that there is signicant scientic
agreement and the product is indeed eective.292 The ratings would need to be changed as new information
came available.293 The companies could present any independent research in order to change the monograph
and hence the rating, but it would have to be conrmed rst.294 Even with a rating system, until conclusive
studies and scientic agreement is reached, labeling in addition to the ratings would be benecial.
Heightened Surveillance
Random testing of products for contamination and monitoring of label claims is yet another option for
increasing the safety of the consumers of dietary supplements, and it is within the FDA's scope of authority.295
The FDA has acknowledged that their current surveillance eorts could be improved.296 This would hopefully
deter the knowingly fraudulent manufactures from using impurities in their products. The downside of this
suggestion is that it will require additional funding in order to be carried out eectively.
Conclusion
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48The adverse events experienced after ingesting ephedra and other dietary supplements have demonstrated
the need for FDA intervention. The FDA has an important role to play in safeguarding the health and safety
of the American public. The FDA has been criticized as contravening the Congressional intent underlying
DSHEA because of its attempts to regulate the dietary supplement industry, when in fact, the FDA has
not overstepped its bounds. The agency has only taken the measures it felt necessary to protect the public
and implement a complex and ambiguous law.297 However, the FDA does need to focus on more eective
procedures and systems for collecting adverse event reports and could take additional steps toward public
awareness. In order for the FDA to address the overall problems with the regulating the dietary supplement
industry eciently and eectively, they will need additional funding.
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